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Abstract
Our interest in lactose as an immunomodulatory molecule results from studies showing that lactose binds to galectin-9, which has been
shown to have various regulatory functions in the immune system including regulation of T-cell responses. Impaired regulation of T helper
(Th)1 and Th17 type immune responses and dysfunction of regulatory T cells (Treg) have been implicated in many human immune-
mediated diseases. In the present study, we investigated the effects of lactose on immune regulation using co-cultures of human peripheral
blood mononuclear cell (PBMC)-derived Treg and effector T cells (Teff) obtained from twenty healthy adults. Treg, i.e. CD4
þCD25þCD1272,
were isolated from PBMC by immunomagnetic separation. The fraction of CD4þCD1272 cells that was depleted of CD25þ cells was used as
Teff. Treg and Teff at a ratio 1:5 were activated and the effects of lactose on the secretion of interferon-g (IFN-g) and IL-17 were analysed
using ELISA for protein and quantitative RT-PCR for mRNA. Treg down-regulated the secretion of both IFN-g (8·8–3·9 ng/ml, n 20, P¼0·003)
and IL-17 (0·83–0·64 ng/ml, n 15, P¼0·04) in co-cultures, while in the presence of lactose the levels of secreted IFN-g and IL-17 remained
high and no down-regulation was observed (16·4 v. 3·99 ng/ml, n 20, P,0·0001, and 0·74 v. 0·64 ng/ml, n 15, P¼0·005, respectively).
We showed that lactose inhibits human Treg-mediated suppression of Th1 and Th17 immune responses in vitro
.
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Lactose, a b-galactoside consisting of galactose and glucose
residues, is the main carbohydrate in mammalian breast milk.
In the first few months of life, lactose provides energy to infants
and supports the growth of lactose-fermenting commensals(1).
During development, the expression of the enzyme lactase
starts to diminish and mammals become lactose intolerant,
but the exact mechanisms of this developmental decline in
enzyme activity are unclear(2,3). However, in some populations,
lactase expression persists due to genetic mutation, and lactose
tolerance is maintained during adult life, allowing the use of
lactose-containing dairy products(4).
Galectin-9 (Gal-9) belongs to the vast group of mammalian
lectins that bind to b-galactosides, such as lactose, with a
conserved carbohydrate recognition domain(5,6). Gal-9 is
expressed by various cell types, such as macrophages, T cells
and intestinal epithelial cells(6–9). Gal-9 is widely distributed
due to its importance in the host system with complex
biological functions including antimicrobial immunity, cell
adhesion, anti-allergic functions, regulatory T-cell (Treg)
differentiation and effector T-cell (Teff) apoptosis
(8–13). Gal-9
mediates its effects by two receptors: cell-surface protein
disulfide isomerase and T-cell Ig and mucin domain-3
(Tim-3)(14,15). It has been demonstrated in animal models that
the Gal-9/TIM-3 pathway regulates antiviral immune responses
in cytotoxic T cells and is crucial for shutting down excessive
T helper (Th)1 and Th17 immune responses(13,15,16). Tim-3-
mediated regulation of Th1 and Th17 immune responses has
been shown in human subjects by Hastings et al.(17). In some
studies, lactose has been used as a Gal-9 antagonist. Similar
to Gal-9 gene silencing, lactose abrogates Gal-9-mediated
immune regulation by limiting its engagement with Tim-3(18).
This results in increased proliferation of T cells and induction
of pro-inflammatory responses with aggravation of clinical
outcomes in mouse models of experimental autoimmune ence-
phalitis and arthritis(13,15,16,19).
Although proper Th1 and Th17 immune responses are
required for host defence in intracellular pathogen clearance
and mucosal antimicrobial immunity, respectively, uncontrolled
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and excessive Th1 and Th17 immune activity may have detrimen-
tal effects and may result in the development of immune-
mediateddiseases(20). Treg, characterisedby theexpressionof sur-
face antigensCD4andCD25and the transcription factor forkhead
box P3 (FOXP3), control inflammation by suppressing the func-
tion of Teff. Treg are thought to maintain immune system homeo-
stasis and tolerance to self-antigens and non-self-antigens(21–23).
In the present study, we investigated the role of lactose as a
potential inhibitor of human Treg-mediated immune regulation
in Th1 and Th17 immune responses to evaluate the possible
effects of dietary lactose on immune function in humans.
Materials and methods
Isolation of human peripheral blood mononuclear cells
and enrichment of T cells
Peripheral blood mononuclear cells (PBMC) were isolated from
twenty healthy donors by Ficoll gradient centrifugation (Ficoll-
Paquee PLUS; GE Healthcare). The collected PBMC were
washed three times with PBS (BioWhittaker) and resuspended
in Roswell Park Memorial Institute (RPMI) 1640 culture medium
(Lonza) supplemented with L-glutamine (Invitrogen), gen-
tamicin (Sigma-Aldrich) and heat-inactivated human AB serum
(Innovative Research). Before cell culture, all cell fractions were
dyed with Trypan Blue for cell counting and viability assessment.
Treg from PBMC populations were enriched using the Regulatory
T Cell IsolationKit II (catalogueno. 130-094-775) according to the
manufacturer’s recommendation (Miltenyi Biotec). First, PBMC
were labelled with a biotinylated antibody cocktail for non-CD4
and CD127 antigens and anti-biotin microbeads, and then the
labelled cells were separated magnetically in an LD column
(Miltenyi Biotec). Cells passing through the column comprised
a pre-enriched CD4þCD1272 cell population, which was further
enriched for Treg by direct magnetic labelling of the surface
antigen CD25. CD4þCD25þCD1272 cells were then separated
on a magnetic MS column (Miltenyi Biotec). The flow-through
fraction of CD4þCD1272 Th cells that was depleted of CD25þ
Treg was used as Teff. Magnetic separation was performed once
for each enriched cell population. The viability of enriched Treg
was .89% and that of enriched Teff was . 83%. The purity
of Treg and Teff was assessed by flow cytometry after magnetic
separation. Typically, over 94% of gated CD4þCD25þ cells,
representing Treg, expressed the transcription factor FOXP3
(Fig. 1(a)). The CD4þCD252CD1272 cell population comprising
.83%ofCD4þ cellswas usedasTeff
(24,25). Thepresent studywas
conducted according to the guidelines laid down in the
Declaration of Helsinki, and all procedures involving human
subjects were approved by the ethics committee of the Helsinki
University Central Hospital. Written informed consent was
obtained from all subjects.
Cell culture
Enriched Teff and Treg were cultivated in ninety-six-well plates












































Fig. 1. Characterisation of human regulatory T cells (Treg) enriched from peripheral blood mononuclear cells using immunomagnetic beads. (a) A fluorescence-
activated cell sorting-based phenotype analysis of enriched Treg in lymphocyte gate. Typically, over 94 % of gated CD4
þCD25þ cells expressed the transcription
factor forkhead box P3 (FOXP3), a marker for Treg. (b) High intracellular protein expression of galectin-9 (Gal-9) in stimulated Treg after 6 d of anti-CD3 and anti-
CD28 stimulation. , IgG1-phycoerythrin of stimulated Treg; , Gal-9-phycoerythrin of stimulated Treg. PerCP, peridinin chlorophyll; APC, allophycocyanin.


















Downloaded from https://www.cambridge.org/core. Helsinki University Library, on 20 Sep 2017 at 12:34:41, subject to the Cambridge Core terms of use, available at
medium consisted of RPMI 1640 (Invitrogen) supplemented
with human heat-inactivated and sterile-filtered 5 % AB
serum, 2 mM-L-glutamine (Invitrogen) and 25mg/ml gentami-
cin (Sigma-Aldrich). Before experimentation, the kinetics of
Gal-9 expression in stimulated Treg obtained from two healthy
individuals was studied. Enriched Treg were stimulated with
anti-CD3 and anti-CD28 for 6 d, and the gene expression of
Gal-9 was analysed at 24 h intervals. The peak transcription
of Gal-9 occurred after 6 d of polyclonal stimulation of Treg
(data not shown). Based on these results, Treg were pre-stimu-
lated for 4 d before the addition of lactose to the co-cultures to
modulate up-regulated endogenous Gal-9 expression. The
expression of Gal-9 protein was analysed by flow cytometry
in stimulated Treg after 6 d of stimulation.
To study the effects of lactose on the function of Treg, first
Treg and Teff were stimulated with 5mg/ml plate-bound
anti-CD3 (BD Biosciences) and soluble 5mg/ml anti-CD28
(BD Biosciences) in separate culture wells for 4 d. Then, Treg
were transferred into a co-culture with Teff at a cell ratio of
1:5 (15 000 Treg:75 000 Teff in 100ml volume per well), and
30 mM-lactose (Flukaw Analytical), 30 mM-sucrose (Fisher
Scientific) or culture medium without added sugars was
added to the cultures. As controls, the Teff were cultured
alone or with only lactose. Cell-culture supernatants were
collected 3 d after the addition of sugars and stored as such
at 2708C, and cultured cells were collected and lysed in
RLT buffer (Qiagen) and stored at 2708C.
ELISA
A modified ELISA was used for measuring interferon-g (IFN-g)
secretion in cell-culture supernatants. Enhanced binding plates
(Thermo Scientific) were coated with human IFN-g capture
antibody (Thermo Fisher Scientific) in a binding buffer
(0·1 M-Na2HPO4) and incubated overnight at þ48C. Blocking
was performed using 1% bovine serum albumin in PBS. The
plates were washed with 0·05 % Tween in PBS. IFN-g in
undiluted culture supernatant samples was detected using bio-
tinylated secondary IFN-g antibody (Thermo Fisher Scientific)
and biotin-specific streptavidin–alkaline phosphatase (Invitro-
gen) with p-nitrophenylphosphate (Sigma-Aldrich) for colour
formation and intensity readings at 405 nm. Recombinant
human IFN-g (R&D Systems) at different dilutions was used
for constructing a standard curve for calculation of the concen-
tration of secreted IFN-g in the samples. Secreted IL-17A in cell-
culture supernatants was detected using the Human IL-17
DuoSet ELISA Kit (catalogue no. DY317) according to the man-
ufacturer’s instructions (R&D Systems). To prevent inter-assay
variation, the supernatant samples from one experiment
including different treatments were always analysed in the
same assay, i.e. on the same ELISA plate. The detection limit
was determined as the lowest standard dilution in the analysis
(0·78 ng/ml for IFN-g and 15·6 pg/ml for IL-17A).
Quantitative RT-PCR
Total RNA was extracted from pelleted and lysed cultured
cells using the RNeasy Mini Kit (Qiagen) with on-column
DNase I treatment. High-Capacity cDNA Reverse Transcription
Kit (Applied Biosystems) was used for reverse transcription.
Real-time detection of target gene complementary DNA ampli-
fication was performed using TaqMan Gene Expression Assays
(Applied Biosystems) for IFN-g (Hs00174143_m1) and
StepOnePlus instrument (Applied Biosystems) for IL-17A
(Hs00174383_m1). RN18S1 (Hs03928985_g1) was used as an
endogenous reference gene to calculate comparative/D cycle
threshold ðDC tÞ values for IFN-g complementary DNA and
IL-17 complementary DNA amplification. The DC t values of
target gene amplification were compared with those of an in-
house calibrator sample for relative values of gene expression.
Flow cytometry
The purity of enriched Teff and Treg was verified by staining with
anti-human CD3-phycoerythrin, CD4-peridinin chlorophyll,
CD8-fluorescein isothiocyanate, CD14-allophycocyanin and
CD25-allophycocyanin (Becton Dickinson) and with appropriate
IgG1 isotype control (Becton Dickinson) and incubating at room
temperature for 20min. Intranuclear staining for FOXP3 was per-
formed with anti-human FoxP3-Alexa 488 (BioLegend) and
isotype control IgG1 (BioLegend) after fixation and permeabilisa-
tion using the FoxP3 Fix/Perm Kit (BioLegend). Stimulated cells
were incubated with GolgiStop (BD Biosciences) for 4 h and
stained with anti-human CD4 and anti-human TIM-3-allophyco-
cyanin (eBioscience) before intracellular staining with
anti-human IFN-g-fluorescein isothiocyanate (BD Pharmingen)
and anti-human IL-17A-phycoerythrin (eBioscience), which
was performed using the BD Cytofix/Cytoperm Fixation/
Permeabilization Kit (BD Biosciences). Gal-9 in stimulated Treg
was stained intracellularly with human anti-Gal9 (BioLegend)
and IgG1k (BioLegend) for isotype control using the BD Cytofix/
Cytoperm Fixation/Permeabilization Kit (BD Biosciences). For
analysis of fluorescence intensity, cells were collected and
resuspended in 300ml of 0·5% bovine serum albumin in PBS
and detected using a FACSCalibur flow cytometer and CellQuest
Pro software (Becton Dickinson). Results were analysed using
FlowJo 7.6 software (Tree Star, Inc.).
Statistical analysis
The normality of quantitative RT-PCR and ELISA data was tested,
and the data were found to not follow Gaussian distribution.
Statistical differences between multiple groups were calculated
using the paired non-parametric Friedman test. Statistical differ-
ences between two data groups were analysed using the paired
non-parametric Wilcoxon test. Data analysis was carried out
using GraphPad Prism 6 software (GraphPad Software, Inc.).
Statistical significance was set at P,0·05.
Results
Human regulatory T cells produce galectin-9 after
stimulation
The kinetics of Gal-9 expression in stimulated Treg collected
from two different individuals was studied to determine the
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optimal time to assess the effects of lactose on Gal-9-mediated
suppression. Enriched Treg were stimulated with anti-CD3 and
anti-CD28 for 6 d, and the gene expression of Gal-9 was
analysed at 24 h intervals. The peak transcription of Gal-9
occurred after 6 d of polyclonal stimulation of Treg (data not
shown). Intracellular Gal-9 production was also detected
in enriched human Treg, i.e. CD4
þCD25þCD1272 after
stimulation with anti-CD3 and anti-CD28 for 6 d (Fig. 1).
Lactose inhibits regulatory T-cell-mediated down-
regulation of pro-inflammatory cytokine production
To measure the effects of lactose on Treg-mediated down-
regulation of Teff pro-inflammatory IFN-g and IL-17 cytokine
production, Teff were cultured as such and in co-cultures
with Treg. In the presence of Treg, there was a decrease in
the levels of IFN-g and IL-17 secreted by Teff from a median
of 8·8 to 3·9 ng/ml for IFN-g (Fig. 2(a); P¼0·003) and from
0·83 to 0·64 ng/ml for IL-17 (Fig. 2(b); P¼0·04). Treg-mediated
suppression was inhibited when lactose was added to the cell
culture, which led to an elevation in the levels of secreted
IFN-g (Fig. 2(a); median 16·4 v. 3·9 ng/ml, P,0·0001) and
IL-17 (Fig. 2(b); median 0·74 v. 0·64 ng/ml, P¼0·005).
No inhibitory effect of Treg could be observed on the transcrip-
tion of IFN-g or IL-17 (Fig. 2(c) and (d)); however, there
was an increase in the relative levels of IFN-g transcripts from
a median of 484 to 1294 when lactose was added to the
co-culture (Fig. 2(c); P,0·0001). No changes were observed
in the levels of IFN-g secreted by stimulated Teff cultured with
lactose when compared with those secreted by stimulated Teff
cultured without lactose (median IFN-g values for
Teff ¼ 38·2 ng/ml, range ¼ 14·86–62·6 ng/ml, and for Teffþ -
lactose ¼ 41·4 ng/ml, range ¼ 3·1–64·5 ng/ml, n 7, P¼0·69).
No changes could be observed in the percentage or fluor-
escence intensity of IFN-g-producing CD4þTIM-3þ cells
when cultured with Treg with or without lactose (n 10). How-
ever, in three of the nine blood donors, lactose, but not
sucrose, increased the percentage of IL-17-producing
CD4þTIM-3þ cells and the intensity of IL-17 in CD4þTIM-3þ
cells (data of one representative individual shown in Fig. 3).
Discussion
Our interest in dietary lactose as an immunomodulatory
molecule results from studies showing that the Tim-3/Gal-9


























































n 19 n 20 n 20 n 15 n 12n 14
n 19 n 20 n 20 n 15
Teff+Treg Teff+Treg+L Teff+Treg+S
Teff Teff+Treg Teff+Treg+L Teff+Treg+S
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n 14 n 11
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Fig. 2. Modulation of the functions of effector T cells (Teff) by regulatory T cells (Treg) and lactose (L) in healthy study subjects. Teff were cultured as such and in
co-cultures with Treg (TeffþTreg) and with TregþL (TeffþTregþL) or sucrose (TeffþTregþS). Treg-mediated down-regulation of interferon-g (IFN-g) (a) and IL-17 (b)
secretion was inhibited by lactose. Lactose increased the transcription of IFN-g (c), but not of IL-17 (d), in Teff co-cultured with Treg. Data are represented as mini-
mum to maximum with the median represented by a horizontal line. Cytokine levels in cell-culture supernatants were assessed with ELISA and relative gene
expression of the cells was assessed with quantitative RT-PCR. P values were calculated using the Wilcoxon signed-rank test for paired samples. Median value
was significantly different from that obtained for Teff: *P¼0·04; **P¼0·003. Median value was significantly different from that obtained for TeffþTreg: †P¼0·005;
††P,0·0001. Median value was significantly different from that obtained for TeffþTregþL: ‡P¼0·01; ‡‡P¼0·0002.
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in vitro and in vivo and can be blocked with lactose. In the
present study, we showed in a remarkable number of healthy
individuals that human Treg-mediated down-regulation of Th1
and Th17 immune responses is specifically inhibited by
lactose, as evidenced by an increased expression of IFN-g
and IL-17 in vitro. The suppressive effect of Treg on IFN-g
expression at both the transcriptional and protein levels was
blocked by lactose, which emphasises the importance of
Gal-9 as a mediator of immune regulation expressed by Treg
and the role of lactose as a potent immunomodulator. When
Teff were stimulated with lactose, no changes were observed
in the secretion of IFN-g. This indicates that the effects of
lactose were mediated by the inhibition of Treg-mediated sup-
pression and not by direct effects on Teff. We also provide
preliminary evidence that lactose may increase IL-17
responses in CD4þTIM-3þ cells in some individuals. The
results of the present study are in agreement with a recent
report showing that human Treg express Gal-9 and that lactose
can block Gal-9-mediated suppression of HIV-specific CD8þ
cells in humans(26). In addition, it has been demonstrated
that human T-cell-derived Gal-9 is a regulator of Th17/Treg
development(27).
Human breast milk, containing 7% lactose, provides infants
with nutrients and immunoprotection, in the form of maternal
antibodies, antimicrobial peptides, immune cells and
cytokines(28,29). Neonates are exposed to enormous amounts
of new microbes, non-pathogens and pathogens and are parti-
cularly susceptible to infection. The adaptive immune system of
a neonate is immature and Th2-biased and the neonatal
immunity relies strongly on innate immunity mechanisms(30,31).
Cederlund et al.(32) are the first to show that breast milk lactose
exhibits immunomodulatory properties by inducing the
transcription of the cathelicidin antimicrobial peptide (CAMP),
gene encoding the antimicrobial protein LL-37 in colonic
epithelial cells and in cells of the innate immune system.
We propose that breast milk lactose could have beneficial
effects on immunity during infancy by indirectly enhancing
the IFN-g and IL-17 responses of Teff. Breast milk lactose
could thus be an important mediator of immunoprotection
against mucosal pathogens, as shown in an animal model by
Sehrawat et al.(16). It has been demonstrated that disaccharides
such as lactulose, which is used for the assessment of small-
intestinal permeability, cross the intestinal barrier in infants
and also in individuals with increased intestinal permeability(33).
In addition, milk oligosaccharides from dietary sources have
been shown to interact with cells of the innate immune
system in the lamina propria and to promote intestinal inflam-
mation through interaction of sialyl(a2,3)lactose and Toll-like
receptor 4 in a mouse model of colitis(34). This provides evi-
dence that food-derived oligosaccharides might play a role in
the regulation of mucosal immunity in the intestine.
Given that oligosaccharides reach lamina propria, it is plaus-
ible that in individuals susceptible to chronic inflammatory
diseases, dietary lactose could induce harmful inflammatory
responses by disrupting Treg-mediated regulation as shown
in the present study. The incidence of autoimmune diseases,
chronic inflammatory disorders and allergy has increased
during the last few decades, especially in Western societies,
and cannot be explained by changes in genetic predisposition.
Versatile environmental factors are thought to play a key role
in these immune-mediated disorders as reviewed by
Mohan(35) and Smyk et al.(36). Uncontrolled Th1 and Th17
immune responses and the inability of Treg to down-regulate
immune responses have been implicated in the pathogenesis
of many human immune-mediated diseases(37). Moreover,
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Fig. 3. Response exhibited by some individuals to lactose (L) through up-regulation of IL-17 production in CD4þTIM-3þ cells. The percentage (a) and fluorescence
intensity (b) of IL-17 in CD4þTIM-3þ cells were increased in the presence of lactose; data for a representative case of one individual in whom lactose induced
an increase in the IL-17 response of CD4þTIM-3þ cells. Teff, effector T cells; Treg, regulatory T cells; S, sucrose; TIM-3, T-cell Ig and mucin domain-3;
APC, allophycocyanin; PE, phycoerythrin. , TeffþTreg; , TeffþTregþL; , TeffþTregþS.
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mation and mast cell degranulation and alleviate allergic status
in mice. The anti-allergic effect of Gal-9 has been found to be
completely inhibited by lactose(12). As mast cells are also
located in the intestinal lamina propria with implications in
gastrointestinal disease(38), the role of dietary lactose in the
exacerbation of allergic inflammation in individuals with
food allergy should be considered. In populations with a
high proportion of lactose-tolerant individuals, due to the
high frequency of lactase gene mutation contributing to the
persistent intestinal lactase production during adulthood, lac-
tose intake from the diet is relatively eminent(4,39,40). Interest-
ingly, the incidence of some immune-mediated diseases is
high among these populations(41–43). It is also possible that
the intestinal problems associated with genetic lactose intoler-
ance may not always be caused by lactose-related osmotic
changes, but could be of immunological origin.
Taken together, lactose has strong immune-modulating
properties, which we have demonstrated in the present
study in vitro in human subjects and which have been
shown earlier both in vitro and in vivo in mice. Physiological
relevance of our preliminary results and effects of dietary lac-
tose on the human gut immune system and health need to be
studied further.
Acknowledgements
The authors thank Anneli Suomela for helping with quantitat-
ive RT-PCR analysis and study nurse Anne Nikkonen for help-
ing with sample collection.
The present study was supported by Semper Limited (M. P.)
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